Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-01-06 | Alex Gorsky, 61, is the Executive Chairman of Johnson & Johnson, a global healthcare products company, having previously served as Chairman and CEO. Mr. Gorsky was named CEO and joined the Board of Johnson & Johnson in April 2012. He was subsequently named Chairman of the Board in December 2012. Mr. Gorsky joined Johnson & Johnson in 1988, serving in various positions of increasing responsibility. In 2004, Mr. Gorsky left Johnson & Johnson to join Novartis Pharmaceuticals Corporation, where he served as head of its pharmaceutical business in North America, before returning to Johnson & Johnson in 2008. Among other qualifications, Mr. Gorsky brings to the Board executive leadership experience, including his service as a chairman and chief executive officer of a large international public company, along with extensive experience in the fields of health and technology. Alex Gorsky (Nominating Committee) joined the Board in 2021 and no compensation was reported for 2021. |
| 2023-01-12 | Alex Gorsky brings to the Board executive leadership experience, as well as brand marketing expertise and extensive experience in the fields of health and technology through his service as a chairman and chief executive officer of a large international public company. Mr. Gorsky, 62, has served as the Executive Chairman of Johnson & Johnson, a global healthcare products company, since January 2022, having previously served as Chairman and CEO. Mr. Gorsky was named CEO and joined the Board of Johnson & Johnson in April 2012. He was subsequently named Chair of the Board in December 2012. Mr. Gorsky joined Johnson & Johnson in 1988, serving in various positions of increasing responsibility. In 2004, Mr. Gorsky left Johnson & Johnson to join Novartis Pharmaceuticals Corporation, where he served as head of its pharmaceutical business in North America, before returning to Johnson & Johnson in 2008. Mr. Gorsky serves on the boards of the Travis Manion Foundation, a non-profit organization that empowers veterans to develop character in future generations, and the National Academy Foundation, a non-profit organization that supports career academies within traditional high schools, and on the Board of Advisors of The Wharton School. Mr. Gorsky is the recipient of the Robert F. Kennedy Human Rights Ripple of Hope Award, and the Prix Galien Roy Vagelos Pro Bono Humanum Award. Other Public Company Boards: Current: International Business Machines Corporation; Johnson & Johnson; JPMorgan Chase & Co. Compensation of Directors: Alex Gorsky received total compensation of $453,185 in 2022. |
| 2024-01-11 | Alex Gorsky brings to the Board executive leadership experience, as well as brand marketing expertise and extensive experience in the fields of health and technology through his service as a chairman and chief executive officer of a large international public company. Mr. Gorsky, 63, is the retired Chief Executive Officer and Executive Chairman of Johnson & Johnson, a global healthcare products company. Mr. Gorsky served as Executive Chairman from January 2022 to January 2023, having previously served as CEO from April 2012 and Chair of the Board from December 2012. Mr. Gorsky joined Johnson & Johnson in 1988, serving in various positions of increasing responsibility. In 2004, Mr. Gorsky left Johnson & Johnson to join Novartis Pharmaceuticals Corporation, where he served as head of its pharmaceutical business in North America, before returning to Johnson & Johnson in 2008. Mr. Gorsky serves on the boards of the Travis Manion Foundation, a non-profit organization that empowers veterans to develop character in future generations, and the National Academy Foundation, a non-profit organization that supports career academies within traditional high schools, and on the Board of Advisors of The Wharton School. Mr. Gorsky is the recipient of the Robert F. Kennedy Human Rights Ripple of Hope Award, and the Prix Galien Roy Vagelos Pro Bono Humanum Award. Other Public Company Boards: Current: International Business Machines Corporation; JPMorgan Chase & Co. Within Last Five Years: Johnson & Johnson. Compensation: 377,043. |
| 2025-01-10 | Alex Gorsky brings to the Board executive leadership experience, as well as brand marketing expertise and extensive experience in the fields of health and technology. |
| Filing Date | Source Excerpt |
|---|---|
| 2019-03-11 | Mr. Gorsky, 58, joined Johnson & Johnson in 1988. He was named company group chairman of the Johnson & Johnson pharmaceutical business in Europe, the Middle East and Africa in 2003. Mr. Gorsky left Johnson & Johnson in 2004 to join Novartis Pharmaceuticals Corporation. Mr. Gorsky returned to Johnson & Johnson in 2008 as company group chairman for Ethicon. He was named chief executive officer and joined the board of directors in April 2012, and was named chairman in December 2012. Committees: Executive Compensation & Management Resources (Chair), Executive, Executive Committee. Compensation: Fees Earned or Paid in Cash $328,389, All Other Compensation $47,506, Total $375,895. |
| 2020-03-09 | Director since: 2014 Age: 59 Committees: Executive, Compensation & Management Resources (Chair), Executive Alex Gorsky Chairman and Chief Executive Officer, Johnson & Johnson |
| 2021-03-08 | Chairman and Chief Executive Officer, Johnson & Johnson. |
| 2022-03-07 | Alex Gorsky, 61, Executive Chairman and Retired CEO, Johnson & Johnson, Director since 2014, Committees: Executive Compensation and Management Resources, Executive. 2021 Director Compensation Table shows total $564,084. |
| 2023-03-06 | Mr. Gorsky, 62, is the former chairman and chief executive officer of Johnson & Johnson, and one of just seven leaders to have served in the dual role of chairman and chief executive officer since the company was listed on the New York Stock Exchange in 1944. He joined Johnson & Johnson in 1988 as a sales representative with Janssen Pharmaceutica. In 2003, he was named company group chairman of the Johnson & Johnson pharmaceutical business in Europe, the Middle East and Africa. Mr. Gorsky left Johnson & Johnson in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company’s pharmaceutical business in North America. Mr. Gorsky returned to Johnson & Johnson in 2008 as company group chairman for Ethicon. In early 2009, he was appointed worldwide chairman of the Surgical Care Group and member of the executive committee. In September 2009, he was appointed worldwide chairman of the Medical Devices and Diagnostics Group, and became vice chairman of the executive committee in January 2011. He was named chief executive officer and joined the board of directors in April 2012, and was named chairman of the board of directors in December 2012. Mr. Gorsky remained chief executive officer until he transitioned to executive chairman at the end of 2021. He currently sits on the boards of Apple, JPMorgan Chase and NewYork-Presbyterian Hospital, and the Travis Manion Foundation, and serves on the Wharton School of the University of Pennsylvania Board of Advisors. |
| 2024-03-11 | Alex Gorsky Former Chairman and Chief Executive Officer, Johnson & Johnson, a global healthcare products company Director since: 2014 Age: 63 Committee: Executive ... 2023 Director Compensation Table Name Alex Gorsky ... Fees Earned or Paid in Cash ($) 400,000 All Other Compensation ($) 169,758 Total ($) 569,758 |
| 2025-03-10 | Mr. Gorsky, 64, is the former chairman and chief executive officer of Johnson & Johnson, and one of just seven leaders to have served in the dual role of chairman and chief executive officer since the company was listed on the New York Stock Exchange in 1944. He joined Johnson & Johnson in 1988 as a sales representative with Janssen Pharmaceutica. In 2003, he was named company group chairman of the Johnson & Johnson pharmaceutical business in Europe, the Middle East and Africa. Mr. Gorsky left Johnson & Johnson in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company’s pharmaceutical business in North America. Mr. Gorsky returned to Johnson & Johnson in 2008 as company group chairman for Ethicon. In early 2009, he was appointed worldwide chairman of the Surgical Care Group and member of the executive committee. In September 2009, he was appointed worldwide chairman of the Medical Devices and Diagnostics Group and became vice chairman of the executive committee in January 2011. He was named chief executive officer and joined the board of directors in April 2012, and was named chairman of the board of directors in December 2012. Mr. Gorsky remained chief executive officer until he transitioned to executive chairman at the end of 2021. He currently sits on the boards of Apple, JPMorgan Chase and the Travis Manion Foundation, and serves on the Board of Advisors for the Wharton School of the University of Pennsylvania. |
| Filing Date | Source Excerpt |
|---|---|
| 2017-03-15 | Mr. Gorsky, 56, was appointed as Chairman, Board of Directors in December 2012... Chief Executive Officer... Chairman, Finance Committee... Mr. Gorsky was an employee of the company, and therefore, received no additional compensation for his service as a director. |
| 2018-03-14 | Mr. Gorsky, 57, was appointed as Chairman, Board of Directors in December 2012... Chief Executive Officer... Chairman, Finance Committee... Mr. Gorsky is an employee of the company, and therefore, received no additional compensation for his service as a Director. |
| 2019-03-13 | Alex Gorsky Management Primary Occupation: Chairman and Chief Executive Officer, Johnson & Johnson Current Committees: Chairman, Finance Mr. Gorsky is an employee of the company, and therefore, received no additional compensation for his service as a Director. |
| 2020-03-11 | Mr. Gorsky, age 59, was appointed as Chairman, Board of Directors in December 2012. He was named Chief Executive Officer, Chairman of the Executive Committee and joined the Board of Directors in April 2012. Mr. Gorsky began his Johnson & Johnson career with Janssen Pharmaceutica Inc. in 1988. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management. In 2001, Mr. Gorsky was appointed President of Janssen Pharmaceutical Inc., and in 2003 he was named Company Group Chairman of the Johnson & Johnson pharmaceutical business in Europe, the Middle East and Africa. Mr. Gorsky left Johnson & Johnson in 2004 to join Novartis Pharmaceuticals Corporation, where he served as head of the pharmaceutical business in North America. Mr. Gorsky returned to Johnson & Johnson in 2008 as Company Group Chairman for Ethicon. In early 2009, he was appointed Worldwide Chairman of the Surgical Care Group and member of the Executive Committee. In September 2009, he was appointed Worldwide Chairman of the Medical Devices and Diagnostics Group. Mr. Gorsky became Vice Chairman of the Executive Committee in January 2011. Mr. Gorsky serves on the Boards of the Travis Manion Foundation, the National Academy Foundation and the Wharton Board of Overseers. He is a Member of the Board of the Business Roundtable and serves as the Chairman of its Corporate Governance Committee. Current Committees: Chair, Finance. Compensation Decisions for 2019 Performance: The Board recognized Mr. Gorsky’s 2019 performance by awarding him an annual performance bonus at 108% of target and long-term incentives at 108% of target. After reviewing market data and other factors, the Board kept Mr. Gorsky's salary rate unchanged at $1,650,000 per year. His salary rate has remained the same since 2018. Total Direct Compensation: $19,380,000. |
| 2021-03-10 | Chairman and Chief Executive Officer, Johnson & Johnson. |
| 2022-03-16 | A. Gorsky CH 61 2012 Executive Chairman, Johnson & Johnson Chair, Finance |
| Filing Date | Source Excerpt |
|---|---|
| 2025-04-07 | Alex Gorsky Retired Chairman and Chief Executive Officer of Johnson & Johnson Age: 64 Director since: 2022 Committees: Audit Committee Public Responsibility Committee 2024 Director compensation table Alex Gorsky $130,000 fees earned in cash, $265,000 stock award, $20,000 other fees, total $415,000. |
Data sourced from SEC filings. Last updated: 2025-08-30